Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
AstraZeneca
Express Scripts
Accenture
Julphar
UBS
Johnson and Johnson
Daiichi Sankyo
Baxter

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,153,964

« Back to Dashboard

Which drugs does patent 7,153,964 protect, and when does it expire?

Patent 7,153,964 protects ZYKADIA and is included in one NDA.

This patent has twenty-four patent family members in twenty countries.
Summary for Patent: 7,153,964
Title:Pyrimidine compounds
Abstract: Pyrimidine derivatives of formula (I) wherein: Qh.sub.1 and Q.sub.2 are independently selected from aryl or carbon linked heteroaryl optionally substituted as defined within; and one of Q.sub.1 and Q.sub.2 or both Q.sub.1 and Q.sub.2 is substituted on a ring carbon by one group selected from sulphamoyl, N--(C.sub.1-4alkyl)sulphamoyl (optionally substituted by halo or hydroxy), N,N-di-(C.sub.1-4alkyl)sulphamoyl (optionally substituted by halo or hydroxy), C.sub.1-4alkylsulphonyl (optionally substituted by halo or hydroxy) or a substituent of the formula (Ia) or (Ia'): wherein Q.sub.1, Q.sub.2, G, R.sup.1, Y, Z, Q.sub.3, n and m are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) inhibitors are also described ##STR00001##
Inventor(s): Pease; Elizabeth Janet (Macclesfield, GB), Breault; Gloria Anne (Macclesfield, GB), Morris; Jeffrey James (Macclesfield, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/220,139
Patent Claim Types:
see list of patent claims
Compound; Process; Composition;

Drugs Protected by US Patent 7,153,964

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,153,964

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0004888.4Mar 1, 2000
PCT Information
PCT FiledFebruary 26, 2001PCT Application Number:PCT/GB01/00782
PCT Publication Date:September 07, 2001PCT Publication Number: WO01/64654

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Chubb
Argus Health
Deloitte
Dow
US Army
Teva
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.